The study of Okuma et al. on 96 patients with advanced lung cancer indicated that overall survival was significantly reduced in patients with high (> 7.32 ng/mL) concentration of plasma sPD-L1 compared with low (< 7.32 ng/mL) sPD-L1 level (13.0 vs. 20.4 months, p = 0.037). The gene discussed is SPDL1; the disease is lung cancer.